Last reviewed · How we verify
ORX750
At a glance
| Generic name | ORX750 |
|---|---|
| Sponsor | Centessa Pharmaceuticals (UK) Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia (PHASE2)
- A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ORX750 CI brief — competitive landscape report
- ORX750 updates RSS · CI watch RSS
- Centessa Pharmaceuticals (UK) Limited portfolio CI